Analyst Price Targets — ASTH
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| April 15, 2026 10:18 am | — | Robert W. Baird | $40.00 | $29.07 | TheFly | Astrana Health price target raised to $40 from $37 at Baird |
| February 2, 2026 12:14 pm | — | BTIG | $40.00 | $22.74 | TheFly | Astrana Health price target lowered to $40 from $45 at BTIG |
| December 12, 2025 11:23 am | Matthew Shea | Needham | $28.00 | $22.46 | TheFly | Astrana Health initiated with a Buy at Needham |
| November 25, 2025 4:33 pm | — | Jefferies | $37.00 | $22.91 | TheFly | Astrana Health price target lowered to $37 from $44 at Jefferies |
| November 24, 2025 11:21 am | Andrew Mok | Barclays | $26.00 | $22.50 | TheFly | Astrana Health price target lowered to $26 from $36 at Barclays |
| April 1, 2025 11:26 am | — | Barclays | $36.00 | $29.86 | TheFly | Astrana Health initiated with an Equal Weight at Barclays |
| March 3, 2025 12:00 pm | — | Robert W. Baird | $50.00 | $26.48 | TheFly | Astrana Health price target lowered to $50 from $86 at Baird |
| October 3, 2024 7:22 am | David Larsen | BTIG | $70.00 | $57.87 | TheFly | Astrana Health price target raised to $70 from $60 at BTIG |
| August 15, 2024 6:34 am | Michael Ha | Robert W. Baird | $67.00 | $46.58 | TheFly | Astrana Health price target raised to $67 from $54 at Baird |
| June 27, 2024 8:09 am | Chris O'Cull | Stifel Nicolaus | $48.00 | $40.50 | StreetInsider | Astrana Health, Inc (ASTH) PT Raised to $48 at Stifel |
Latest News for ASTH
On April 16, 2026, Astrana Health Inc (ASTH) shares rose 4.7%, bringing the current price to $30.60. The stock has shown a strong performance over the past mont
Valuation Assessment of Astrana Health Inc (ASTH) On April 13, 2026, Astrana Health Inc (ASTH) shares rose 4.5% today, bringing the current price to $28.88. The
ALHAMBRA, Calif., April 10, 2026 /PRNewswire/ -- Astrana Health, Inc. ("Astrana," and together with its subsidiaries and affiliated entities, the "Company") (NASDAQ: ASTH), a physician-centric, technology-enabled healthcare company empowering providers to deliver accessible, high-quality, and high-value care to all, today announced that leadership is participating in the following upcoming investor conferences: The…
Astrana Health, Inc. offers a mispriced growth opportunity, combining 20–30% top and bottom line growth with strong free cash flow and operational leverage. ASTH's risk-bearing, tech-enabled model drives industry-leading G&A efficiency (6.8%), diversified revenue streams, and resilience against reimbursement or membership volatility. Despite 56% revenue growth and robust EBITDA expansion, ASTH trades at deep…
JPMorgan Chase and Co. trimmed its holdings in Astrana Health, Inc. (NASDAQ: ASTH) by 30.3% in the third quarter, according to the company in its most recent filing with the SEC. The fund owned 64,298 shares of the company's stock after selling 27,903 shares during the quarter. JPMorgan Chase and Co. owned 0.11%
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for ASTH.
U.S. House Trading
No House trades found for ASTH.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.